Abstract 1421P
Background
Imaging reading for endpoint evaluation in clinical trials presents challenges in reproducibility and accuracy, limiting the use of novel endpoints beyond human capabilities. This analysis explored the feasibility of AI-powered intracranial response assessment and uncovered novel imaging prognosticators in the phase III CROWN study.
Methods
72 patients (40 patients in the crizotinib arm, 32 patients in the lorlatinib arm) with CNS metastases at baseline in the CROWN study (NCT03052608) underwent intracranial response assessment using MRI at screening and then every 8 weeks until disease progression. VBrain, an FDA-approved brain tumor AI, was used to generate response assessments that were compared with those performed by 2 neuro-radiologists from the blinded independent central review group for the study using modified RECIST (mRECIST). The sum of tumor diameter changes at first on-treatment tumor scan from baseline, denoted as early tumor shrinkage (ETS), was assessed with Cox's proportional hazard model to estimate drug efficacy.
Results
For target lesion measurements, AI showed a high correlation with the independent readers (Pearson correlation coefficient ρ=0.94). The intracranial objective response rate assessed by AI was 27.5% and 71.9% in the crizotinib and lorlatinib arms, respectively. Among 666 time-point assessments, discordance rates were 35.1% between AI and reader 1, 33.5% between AI and reader 2, and 35.7% between the 2 readers. The time to intracranial progression (iTTP) derived from AI and human readers showed no significant difference by log-rank test. AI tracked 394 tumors beyond mRECIST, with a median ETS of -41.8% for all these lesions vs -24.4% for target lesions by mRECIST. Brain-wide ETS better predicted systemic TTP (HR 0.40, [95% CI 0.21–0.76], p<0.01), while target-lesion ETS showed no significant difference (HR 0.59, [95% CI 0.32–1.09], p=0.09) by ETS categories > or <= to median ETS.
Conclusions
There was high agreement between AI and readers in lesion measurement, response assessment, and endpoint evaluations in the CROWN study. ETS leveraging all brain lesions may uncover a potential prognostic indicator of response in ALK-positive advanced NSCLC patients.
Clinical trial identification
NCT03052608. Last update posted: May 31, 2022.
Editorial acknowledgement
Legal entity responsible for the study
Vysioneer Inc.
Funding
Vysioneer Inc.
Disclosure
C. Duan, A. Schayowitz, P. Selaru, K.D. Wilner: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer Inc. Y. Chang, C. Liang, P. Chiang, V. Lin, Y. Yang, J. Lu: Financial Interests, Personal, Full or part-time Employment: Vysioneer Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20